Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
22104: Izokibep in Active Psoriatic Arthritis
2022-501362-22-00Phase 3Completed
- Sponsor
- Acelyrin
- Start
- Mar 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Izokibep with Placebo (2 arms). Primary endpoint: ACR50 at Week 16. Started Mar 2023; status: completed.
02
Drugs
izokibep
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2022-501362-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501362-22-00.